ScandiDos AB (publ) (SDOS.ST)
SEK 1.34
(1.13%)
SEK 1.34
(1.13%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -14.64 Million SEK | -60.62% |
| 2022 | -9.11 Million SEK | -24.27% |
| 2021 | -7.33 Million SEK | -424.52% |
| 2020 | -1.39 Million SEK | 89.35% |
| 2019 | -13.13 Million SEK | 26.05% |
| 2018 | -17.76 Million SEK | -53.58% |
| 2017 | -11.56 Million SEK | 12.1% |
| 2016 | -13.15 Million SEK | 7.62% |
| 2015 | -14.24 Million SEK | 3.0% |
| 2014 | -14.68 Million SEK | -249.6% |
| 2013 | -4.2 Million SEK | -100.67% |
| 2012 | -2.09 Million SEK | -1022.03% |
| 2011 | 227 Thousand SEK | -29.28% |
| 2010 | 321 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -639 Thousand SEK | 91.61% |
| 2023 Q1 | -5.61 Million SEK | -357.94% |
| 2023 FY | -14.64 Million SEK | -60.62% |
| 2023 Q4 | -7.61 Million SEK | -3362.73% |
| 2023 Q3 | -220 Thousand SEK | 81.53% |
| 2023 Q2 | -1.19 Million SEK | 78.8% |
| 2022 Q4 | 2.17 Million SEK | 199.18% |
| 2022 Q1 | -7.09 Million SEK | -329.8% |
| 2022 FY | -9.11 Million SEK | -24.27% |
| 2022 Q2 | -2 Million SEK | 71.74% |
| 2022 Q3 | -2.19 Million SEK | -9.53% |
| 2021 Q2 | -1.95 Million SEK | 38.63% |
| 2021 Q4 | -1.65 Million SEK | -196.94% |
| 2021 FY | -7.33 Million SEK | -424.52% |
| 2021 Q1 | -3.17 Million SEK | -430.72% |
| 2021 Q3 | -556 Thousand SEK | 71.5% |
| 2020 Q3 | -835 Thousand SEK | -160.77% |
| 2020 Q4 | -599 Thousand SEK | 28.26% |
| 2020 FY | -1.39 Million SEK | 89.35% |
| 2020 Q1 | -1.33 Million SEK | 64.46% |
| 2020 Q2 | 1.37 Million SEK | 202.61% |
| 2019 Q4 | -3.76 Million SEK | -133.89% |
| 2019 Q3 | -1.61 Million SEK | 60.01% |
| 2019 FY | -13.13 Million SEK | 26.05% |
| 2019 Q1 | -3.72 Million SEK | -780.85% |
| 2019 Q2 | -4.02 Million SEK | -8.13% |
| 2018 Q3 | -2.54 Million SEK | 59.25% |
| 2018 Q4 | -423 Thousand SEK | 83.35% |
| 2018 FY | -17.76 Million SEK | -53.58% |
| 2018 Q2 | -6.23 Million SEK | 27.16% |
| 2018 Q1 | -8.56 Million SEK | -3900.47% |
| 2017 Q4 | -214 Thousand SEK | 93.3% |
| 2017 FY | -11.56 Million SEK | 12.1% |
| 2017 Q1 | -4.66 Million SEK | -65.12% |
| 2017 Q2 | -3.49 Million SEK | 25.03% |
| 2017 Q3 | -3.19 Million SEK | 8.7% |
| 2016 Q1 | -5.51 Million SEK | -16.23% |
| 2016 FY | -13.15 Million SEK | 7.62% |
| 2016 Q4 | -2.82 Million SEK | -23.32% |
| 2016 Q3 | -2.29 Million SEK | 9.41% |
| 2016 Q2 | -2.52 Million SEK | 54.16% |
| 2015 Q1 | -6.69 Million SEK | -29.81% |
| 2015 Q4 | -4.74 Million SEK | -187.4% |
| 2015 Q2 | -1.15 Million SEK | 82.77% |
| 2015 Q3 | -1.65 Million SEK | -43.19% |
| 2015 FY | -14.24 Million SEK | 3.0% |
| 2014 FY | -14.68 Million SEK | -249.6% |
| 2014 Q4 | -5.15 Million SEK | -461.66% |
| 2014 Q2 | -3.34 Million SEK | 36.42% |
| 2014 Q1 | -5.26 Million SEK | -65.92% |
| 2014 Q3 | -918 Thousand SEK | 72.56% |
| 2013 Q4 | -3.17 Million SEK | -430.07% |
| 2013 FY | -4.2 Million SEK | -100.67% |
| 2013 Q1 | -1.06 Million SEK | -419.76% |
| 2013 Q2 | -921 Thousand SEK | 13.76% |
| 2013 Q3 | 961 Thousand SEK | 204.34% |
| 2012 Q4 | 334 Thousand SEK | 116.97% |
| 2012 Q3 | -1.96 Million SEK | 0.0% |
| 2012 FY | -2.09 Million SEK | -1022.03% |
| 2011 FY | 227 Thousand SEK | -29.28% |
| 2010 FY | 321 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 81.183% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 114.152% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 114.152% |
| Arcoma AB | 2.56 Million SEK | 671.256% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 89.416% |
| BICO Group AB (publ) | -835.7 Million SEK | 98.247% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 158.642% |
| CellaVision AB (publ) | 130.3 Million SEK | 111.24% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 81.644% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | 49.816% |
| C-Rad AB (publ) | 35.52 Million SEK | 141.225% |
| Duearity AB (publ) | -26.19 Million SEK | 44.074% |
| Dignitana AB (publ) | -17.36 Million SEK | 15.642% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 84.55% |
| Getinge AB (publ) | 2.41 Billion SEK | 100.607% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 78.453% |
| Iconovo AB (publ) | -45.89 Million SEK | 68.085% |
| Integrum AB (publ) | 4.03 Million SEK | 463.226% |
| Luxbright AB (publ) | -25.37 Million SEK | 42.278% |
| Mentice AB (publ) | -2.81 Million SEK | -419.95% |
| OssDsign AB (publ) | -130.49 Million SEK | 88.776% |
| Paxman AB (publ) | 8.33 Million SEK | 275.834% |
| Promimic AB (publ) | -9.22 Million SEK | -58.827% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 90.843% |
| SciBase Holding AB (publ) | -55.58 Million SEK | 73.649% |
| Sectra AB (publ) | 428.38 Million SEK | 103.419% |
| Sedana Medical AB (publ) | -59.61 Million SEK | 75.429% |
| Senzime AB (publ) | -134.14 Million SEK | 89.082% |
| SpectraCure AB (publ) | -20.44 Million SEK | 28.345% |
| Stille AB | 26.64 Million SEK | 154.969% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 99.62% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 115.952% |